Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

Ecteinascidin 743 (ET-743) is a potent antitumor agent from the Caribbean tunicate Ecteinascidia turbinata and is presently in clinical trials for human cancers. The aim of this study was to assess the nature of the interaction between ET-743 and other antineoplastic agents using the combination index method of Chou and Talalay to better understand how ET-743 might be used clinically. We examined the cytotoxic effect of ET-743 combined with six other antineoplastic agents on human breast cancer cell lines, MX-1, MCF7, and P-glycoprotein overexpressing MCF7/DXR to different schedules. Pretreatment with paclitaxel for 24 h before ET-743 was the most effective combination regimen in all three breast cancer cell lines. Furthermore, sequential treatment with paclitaxel followed by ET-743 increased the antitumor effects in nude mice bearing MX-1 mammary carcinoma xenografts without increasing toxicity. These results suggest that the combination of ET-743 and paclitaxel should be assessed in clinical trials for the treatment of breast cancer.

[1]  K. Pienta,et al.  Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. , 1998, Cancer research.

[2]  R. Mantovani,et al.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Y. Pommier,et al.  Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M D'Incalci,et al.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. , 2001, European journal of cancer.

[5]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[6]  M. D’Incalci,et al.  Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[8]  S. Langdon,et al.  High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Schwartz,et al.  Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  E. Raymond,et al.  In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[12]  Paul A. Keifer,et al.  Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata , 1990 .

[13]  K. Kohn,et al.  DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. , 1996, Biochemistry.

[14]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.